Overview

S0701, Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori (H. Pylori)

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to compare the effectiveness of three different antibiotic regimens against Helicobacter pylori (H. pylori).
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Southwest Oncology Group
Collaborator:
Bill and Melinda Gates Foundation
Treatments:
Anti-Bacterial Agents
Dexlansoprazole
Lansoprazole
Criteria
Inclusion Criteria:

- positive Urea Breath Test documenting H. pylori infection

- age 21 - 65 years

- no known allergies to study drugs

- only member of household participating in study

- no known medical conditions (other than H. pylori) that would preclude or require
antibiotic therapy

- patients must be willing to discontinue alcohol use for 15 days (maximum duration of
treatment plus one day)

- patients must be willing to discontinue use of antacids for duration of study
treatment

- patients must not have used proton pump inhibitors (PPI) within 30 days of
registration. Patients also must be willing to stop using non-study provided PPIs
until the completion of the 6 week follow-up contact.

- patients must not have been treated with antibiotics for H. pylori in the past and
must not have taken any other antibiotics within 30 days of registration.

- patients must be willing to return for 2 follow-up visits: 6 weeks after randomization
following completion of treatment & 1 year after randomization

- patients must be willing to allow submission of blood for assays of serum markers of
bacterial virulence and host genetic susceptibility and environmental factors and
provide consent for use of specimens.

Exclusion Criteria:

- current use of anti-retroviral therapy for HIV or AIDS

- diagnosed congestive hear failure

- renal failure requiring dialysis

- diagnosed hepatic failure resulting in hyperbilirubinemia

- any current or prior malignancy except: adequately treated basal or squamous cell skin
cancer, in situ cervical cancer, adequately treated Stage I or Stage II cancer from
which the patient has been disease free for 5 years

- pregnancy or nursing mothers